Trivascular Technologies (NASDAQ: TRIV) and Obalon Therapeutics (NASDAQ:OBLN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

43.0% of Obalon Therapeutics shares are held by institutional investors. 16.4% of Obalon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Trivascular Technologies and Obalon Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trivascular Technologies 0 0 0 0 N/A
Obalon Therapeutics 1 0 3 0 2.50

Obalon Therapeutics has a consensus price target of $15.25, suggesting a potential upside of 69.63%. Given Obalon Therapeutics’ higher probable upside, analysts clearly believe Obalon Therapeutics is more favorable than Trivascular Technologies.


This table compares Trivascular Technologies and Obalon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trivascular Technologies -143.61% -766.90% -66.97%
Obalon Therapeutics -393.79% -57.80% -45.74%

Valuation and Earnings

This table compares Trivascular Technologies and Obalon Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trivascular Technologies N/A N/A N/A N/A N/A
Obalon Therapeutics $4.98 million 30.37 -$27.12 million ($6.90) -1.30

Trivascular Technologies has higher revenue, but lower earnings than Obalon Therapeutics.


Obalon Therapeutics beats Trivascular Technologies on 7 of the 8 factors compared between the two stocks.

Trivascular Technologies Company Profile

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Obalon Therapeutics Company Profile

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive News & Stock Ratings for Trivascular Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies Inc and related stocks with our FREE daily email newsletter.